@article {MIYAMOTO301, author = {MORIKAZU MIYAMOTO and MASASHI TAKANO and TADASHI AOYAMA and HIROAKI SOYAMA and HIROKI ISHIBASHI and KENTO KATO and HIDEKI IWAHASHI and KAZUKI TAKASAKI and MIKA KUWAHARA and HIROKO MATUURA and TAKAHIRO SAKAMOTO and TOMOYUKI YOSHIKAWA and KENICHI FURUYA}, title = {Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition}, volume = {38}, number = {1}, pages = {301--306}, year = {2018}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To investigate whether XIAP down-regulation and autophagy inhibition sensitize ovarian clear cell cancer cells to cisplatin. Materials and Methods: The ovarian clear cancer cell line KK was used for in vitro analysis. Hydroxychloroquine (HCQ) and phenoxodiol (PXD) or embelin were used as autophagy and XIAP inhibitors, respectively. Non-specific and XIAP-specific siRNAs were transfected using Lipofectamine. Cytotoxicity was assessed by MTT assays. Protein expression was confirmed by western blotting. Results: In KK, down-regulation of XIAP using specific siRNAs together with HCQ treatment enhanced the anti-tumor effect of cisplatin. Although embelin sensitized KK to cisplatin through XIAP down-regulation, it induced autophagy. However, PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition. Expression of Atg7, Atg12, and Beclin 1 was decreased after PXD treatment. Conclusion: PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition and could be a new candidate for ovarian clear cell carcinoma treatment.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/1/301}, eprint = {https://ar.iiarjournals.org/content/38/1/301.full.pdf}, journal = {Anticancer Research} }